|
Yu.A. Kupriyanov, P.I. Rasner, I.M. Rokhlikov, A.A. Akrikidi, V.V. Soloviev, A.A. Markov, E.V. Nozdrin, L.A. Logvinov, R.P. Vasilevskiy, K.S. Skrupskiy, D.Yu. Pushkar, M.A. Putilovskiy, O.I. Epstein
The experience of using drug Afalaza for treatment of lower urinary symptoms in treatment-naïve patients with benign prostatic hyperplasia
|
№3 / 2019
|
|
A.V. Sivkov, S.A. Golovanov, L.V. Zhukova
Prediction of the effectiveness of the therapy of LUTS/BPH by Serenoa repens extracts
|
№3 / 2019
|
|
D.Yu. Pushkar, P.I. Rasner, D.V. Kotenko, A.N. Gerasimov, S.A. Shabalkin
Treatment of patients with lower urinary tract symptoms in Moscow
|
№3 / 2019
|
|
G.G. Krivoborodov, E.I. Tur
Efficiency and safety of silodosin for treatment of lower urinary tract symptoms, associated of benign prostatic hyperplasia
|
№2 / 2019
|
|
A.V. Kuz’menko, V.V. Kuz’menko, T.A. Gyaurgiev
The efficacy of fesoterodine in patients after transurethral resection of the prostate
|
№1 / 2019
|
|
I.O. Meshkov, E.V. Kulchavenya, S.Yu. Shevchenko, A.I. Neimark
Patients with newly diagnosed benign prostatic hyperplasia
|
№4 / 2018
|
|
A.A. Kamalov, A.M. Takhirzade
Approaches to medical management of patients with high risk of progressing of benign prostatic hyperplasia depending on concomitant erectile dysfunction
|
№3 / 2018
|
|
R.E. Amdii, A.S. Al' Shukri
Extract of Serenoa repens in the treatment of benign prostatic hyperplasia and lower urinary tract symptoms
|
№2 / 2018
|
|
O.B. Loran, A.A. Seregin Jr
The effectiveness and safety of Omnik OCAS in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia in the routine clinical practice in the Russian Federation (prospective multi-center observing program)
|
№2 / 2018
|
|
A.I. Neimark, A.V. Davydov, R.T. Aliev
The effects of combination therapy with 5α-reductase inhibitor and α-blocker on the prognosis of BPH
|
№2 / 2018
|
|
A.A. Kamalov, A.M. Takhirzade
Current approaches to conservative treatment of men with concomitant benign prostatic hyperplasia and erectile dysfunction
|
№6 / 2017
|
|
I.N. Orlov, S.V. Popov, A.G. Martov, E.A. Gallyamov, S.M. Malevich, I.V. Sushina, E.A. Grin’, A.E. Sanzharov, A.B. Novikov, V.P. Sergeev, A.D. Kochkin
Comparative assessment of treatments for prostate adenoma greater than 100 cm3
|
№6 / 2017
|
Русский
